Your browser doesn't support javascript.
loading
The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia.
Ali, Sahra; Dunmore, Helen-Marie; Karres, Dominik; Hay, Justin L; Salmonsson, Tomas; Gisselbrecht, Christian; Sarac, Sinan B; Bjerrum, Ole W; Hovgaard, Doris; Barbachano, Yolanda; Nagercoil, Nithyanandan; Pignatti, Francesco.
Affiliation
  • Ali S; European Medicines Agency, London, United Kingdom sahra.ali@ema.europa.eu.
  • Dunmore HM; Medicines and Healthcare Products Regulatory Agency Licensing, London, United Kingdom.
  • Karres D; European Medicines Agency, London, United Kingdom.
  • Hay JL; Medicines and Healthcare Products Regulatory Agency Licensing, London, United Kingdom.
  • Salmonsson T; Medical Products Agency, Uppsala, Sweden.
  • Gisselbrecht C; Hôpital Saint Louis Institut d'Hématalogie, Paris, France.
  • Sarac SB; Danish Medicines Agency, Copenhagen, Denmark.
  • Bjerrum OW; Danish Medicines Agency, Copenhagen, Denmark.
  • Hovgaard D; Danish Medicines Agency, Copenhagen, Denmark.
  • Barbachano Y; Medicines and Healthcare Products Regulatory Agency Licensing, London, United Kingdom.
  • Nagercoil N; Medicines and Healthcare Products Regulatory Agency Licensing, London, United Kingdom.
  • Pignatti F; European Medicines Agency, London, United Kingdom.
Oncologist ; 24(5): e171-e179, 2019 05.
Article de En | MEDLINE | ID: mdl-30898889

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Leucémie aigüe myéloïde / Protocoles de polychimiothérapie antinéoplasique / Agrément de médicaments / Gemtuzumab Type d'étude: Clinical_trials / Etiology_studies / Risk_factors_studies / Systematic_reviews Limites: Humans Pays/Région comme sujet: Europa Langue: En Journal: Oncologist Sujet du journal: NEOPLASIAS Année: 2019 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Leucémie aigüe myéloïde / Protocoles de polychimiothérapie antinéoplasique / Agrément de médicaments / Gemtuzumab Type d'étude: Clinical_trials / Etiology_studies / Risk_factors_studies / Systematic_reviews Limites: Humans Pays/Région comme sujet: Europa Langue: En Journal: Oncologist Sujet du journal: NEOPLASIAS Année: 2019 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: Royaume-Uni